Eli Lilly and Co

Boehringer Ingelheim and Eli Lilly's Jardiance may prevent worsening of diabetic eye disease in type 2 diabetes patients, per JAMA Ophthalmology. Analysis of over 80,000 patients showed Jardiance users had 22% lower risk of existing diabetic eye disease worsening compared to DPP4 inhibitor users. The study suggests Jardiance's potential benefit in managing diabetic retinopathy.

Novo Nordisk's CagriSema, a weight loss drug, achieved 22.7% weight loss in REDEFINE 1 trial but fell short of the 25% target, causing a stock price drop. The drug combines cagrilintide and semaglutide, with potential for further exploration.

Novo Nordisk's CagriSema obesity shot showed 20.4% weight loss over 68 weeks, falling short of the 25% target. The results align with Eli Lilly's Zepbound, while Lilly's retatrutide showed up to 24% weight loss. Novo's shares dropped 27%, erasing $120 billion in market value, while Lilly's rose 10%. Novo plans another trial to optimize doses and aims for CagriSema approval by late next year.

Novo Nordisk's CagriSema weight loss drug missed expectations in a late-stage trial, causing a 24% stock drop. The drug helped patients reduce weight by 22.7%, below the forecasted 25%. Despite this, Novo Nordisk stated CagriSema outperformed Wegovy and was on par with best-in-class treatments. The trial involved 3,400 participants over 68 weeks, with plans for regulatory submission by 2025.

Novo Nordisk's CagriSema showed superior weight loss in REDEFINE 1 trial, but fell short of expectations, causing stock decline. Competitors like Eli Lilly saw gains.

Novo Nordisk's CagriSema obesity drug trial results showed 22.7% weight loss, below the expected 25%, causing a $125 billion market value loss. The drug combines semaglutide and cagrilintide, aiming to be a successor to Wegovy. Despite the disappointment, Novo Nordisk plans a new trial and regulatory submission by 2025.

Novo Nordisk's next-gen obesity treatment CagriSema showed less weight loss than expected, causing a 20% share drop and £70B market value loss. The treatment, combining semaglutide and cagrilintide, induced 22.7% weight loss vs. 22.5% by Lilly's Mounjaro. Both firms race to develop oral drugs by 2025, aiming to improve weight loss and reduce side effects. The weight loss market is projected to grow from $24B in 2023 to over $100B by 2030.

Innovent Biologics announced China's NMPA approval of DOVBLERON®, a next-gen ROS1 TKI for previously treated ROS1-positive NSCLC. DOVBLERON®, Innovent's 13th commercial product, addresses unmet needs, especially for patients with brain metastases and resistance to prior ROS1 TKIs. A second NDA for DOVBLERON® was accepted for ROS1-positive NSCLC patients without prior ROS1 TKI treatment.

FDA says no shortage of Eli Lilly's weight loss and diabetes drugs, allowing compounding pharmacies to continue making cheaper copies for 60-90 days. Lilly warns against marketing unapproved versions of tirzepatide. Novo Nordisk's Wegovy still in shortage. Compounding pharmacies argue shortage persists.

Eli Lilly plans to test its GLP-1 drug, tirzepatide, for addiction treatment. The drug may counteract hedonistic pursuits, reducing opioid overdose risk. It also improved sleep apnea symptoms and reduced all-cause mortality, making it a candidate for life-extension research.